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ABBREVIATIONS 
 
AFAP - Attenuated Familial Adenomatous Polyposis 
APC - Adenomatous Polyposis Coli gene 
CIMP - CpG Island Methylator Phenotype 
CIN - Chromosomal instability 
CRC - Colorectal cancer 
DFS - Disease free survival 
EOCRC - Early onset colorectal cancer 
FAP - Familial Adenomatous Polyposis 
FOBT - Faecal Occult Blood Test  
HNPCC - Hereditary Non Polyposis Colorectal Cancer 
IBD - Inflammatory bowel diseases 
IHC - immunohistochemistry 
LOH - Loss of Heterozygosity 
MAP - MYH-associated polyposis 
MMR - Mismatch Repair 
MSI - Microsatellite instability 
TS - Thymidylate synthase 
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1   INTRODUCTION 
 
 
 
Colorectal cancer (CRC) is one of the major causes of cancer death worldwide. Although 
the incidence is now declining in most western countries by 2–3% annually [1], particularly 
among individuals aged over 50 years, due to improved adherence to screening programs 
with early detection of colorectal cancer resulting in reduced overall mortality. However, 
the modern lifestyle changes in less developed countries has led to an increased 
incidence of CRC, in populations where this cancer was less frequent, causing a 
significant impact on public health [2]. Moreover, recent studies suggest an alarming 
increase in the incidence of early onset colorectal cancers (EOCRC) developing among 
adults younger than 50 years of age, typically below the screening age [3,4]. However, the 
clinical significance of these epidemiologic findings has not been clarified and especially 
why young adults without a predisposing genetic abnormality develop colorectal cancer is 
still unclear. 
 
1.1   Epidemiology and risk factors 
 
Colon cancer is the second most frequent cancer in developed countries in terms of 
incidence. Moreover, CRC is the third and fourth cause of death from cancer in women 
and men, respectively. 
Worldwide, more than 1.2 million new cases of colorectal cancer are diagnosed each year, 
while the number of annual deaths from this cancer is over 600,000 [5]. Significant 
geographical variations with regard to the incidence of cancer in different countries have 
Clinicopathological and molecular features 
of sporadic early onset colorectal cancer 
 
 
 
6 
 
 
 
been observed; however, comparisons between countries can be problematic due to 
differences in the availability of epidemiological data. High incidence is found in northern 
Europe, North America, Australia and recently in Japan, while a low incidence is reported 
in Africa and central Asia [1]. Although overall statistically significant decreases in CRC 
incidence and mortality from 1999 through 2008 for both men and women and in virtually 
all racial and ethnic groups were reported in North America, in 2014 it was estimated that 
more than 135.000 people were diagnosed with colorectal cancer and more than 50.000 
died as a result of it [6]. Incidence rates have risen in many parts of the world, and 
increases are most prominent in Asia and Eastern Europe. On the contrary, CRC rates 
have practically stabilized or decreased in developed countries mainly related to the 
diffusion of screening programs. In particular, the CRC incidence and mortality rates are 
decreasing among all age groups over 50 years old, yet rising constantly in young adults 
for whom screening use is limited and symptoms may go unrecognized [7,8]. 
In Emilia-Romagna region, the incidence of colon cancer in males and females is 77.2 and 
59.1 per 100,000 population, respectively, with a mortality rate of 32.8 and 25.2 [9]. A 
matter of extreme importance is the steady and progressive increase of the incidence over 
the last twenty years, related to a general improvement of the socio-economic conditions 
resulting in a greater dietary caloric intake and obesity in the general population, 
considered to be among the most important risk factors for the development of these 
tumours [10]. 
Outside of screening programs, most CRCs are diagnosed in advanced stages of the 
disease, when tumour invasion or metastasis have already developed, leading to a global 
5-year survival rate of approximately 50%. However, decreased CRC incidence and 
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mortality rates have been shown by recent trends, due to not only screening efficacy on 
early detection and prevention of neoplastic and pre-neoplastic lesions, but also to 
reduced exposure to risk factors and more effective treatment. Moreover, nowadays 
screening programs assess patient risk stratification, taking into consideration patients’ 
personal, familial and clinical history, in order to identify those at high-risk and to determine 
the most adequate screening strategy. For instance, subjects with a familial history of CRC 
have a greater risk of developing CRC, from 2 to 6 times higher than the general 
population, therefore, requiring a more intensive surveillance (Table 1). 
 
Table 1. Family History and Individual Risk for Colorectal Cancer (CRC)[7] 
 
Family history  Approximate lifetime risk 
No history of CRC or adenoma (%) 6 
One second-degree or third-degree relative with CRC 1.5-Fold increase 
One first-degree relative with an advanced adenomatous polyp 2-Fold increase 
One first-degree relative with colon cancer 2- to 3-Fold increase 
Two second-degree relatives with colon cancer 2- to 3-Fold increase 
Two first-degree relatives with colon cancer 3- to 4-Fold increase 
First-degree relative with CRC diagnosed at <50 y 3- to 4-Fold increase 
 
Up to 4-5% of all CRCs are related to two main hereditary syndromes, the Familial 
Adenomatous Polyposis (FAP) and the Lynch syndrome or Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC), which will be described further in a successive paragraph. 
The presence of an inflammatory bowel disease (Crohn’s disease or Ulcerative colitis) is 
also a risk factor for CRC, especially in the case of panniculitis lasting more than 7 years. 
In these conditions, CRC can develop from an adenomatous dysplastic area within the 
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affected colonic mucosa, which needs to undergo surgical resection in case areas with 
high-grade dysplasia are present. 
The relationship between lifestyle, dietary habits and CRC cancer have been investigated; 
obesity, sedentary lifestyle, smoking, an excessive calorie and alcoholic intake, a high-fat 
diet and low fibre consumption have all been associated with an increased risk of 
developing CRC [10]. Furthermore, epidemiological studies have clearly demonstrated a 
significant correlation between CRC and obesity. In particular, in the last 20 years, there 
has been a considerable rise of the incidence of obesity worldwide in parallel with an 
increase of CRC, especially in areas where the incidence was low. Moreover, several 
prospective studies have shown an increased risk in subjects with a Body Mass Index >30. 
The molecular pathways of the obesity-colorectal cancer association are multi-factorial, 
related to several mechanisms such as the insulin-IGF1 axis, the effect of adipokines and 
inflammation. 
 
1.2   Pathogenesis of colorectal cancer 
 
The CRC carcinogenesis is characterized by two main stages: the "initiation" that 
represents the transition from normal epithelium to adenoma, and the "promotion" phase 
that marks the passage from adenoma to carcinoma. Several oncogenes and tumour-
suppressor genes are responsible for specific genetic alterations for each of these two 
phases. Such genetic alterations influence proliferation, differentiation and apoptosis, as 
well as cell polarization and phenotype of the colonic mucosa, and can be inherited or 
acquired. The inherited genetic alterations or "germline mutations" are responsible for the 
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development of hereditary colorectal cancers (FAP, HNPCC). Acquired genetic mutations 
or "somatic mutations" lead to the development of sporadic tumours, which account for the 
majority of CRCs. 
Three pathogenic pathways are known to lead to the development of CRC, all 
characterized by a progressive accumulation of mutations: the chromosomal instability 
pathway (CIN), the Microsatellite Instability (MSI) pathway and the CpG Island Methylator 
Phenotype (CIMP) pathway [11]. 
 
1.2.1   I - The chromosomal instability pathway 
 
 
Most CRCs occurs sporadically through the chromosomal instability pathway (CIN), 
associated with the “adenoma-carcinoma sequence” [12], considered the major 
pathogenic pathway which seems to involve not only adenomatous polyps but also the 
serrated adenomas (Figure 1). Almost all CRCs arise from adenomas (80% from 
adenomatous polyps, 20% serrated adenomas) and the adenoma-carcinoma sequence is 
supported by epidemiological, clinical/pathological and genetic evidence [11]. Indeed, 
epidemiological studies have shown an association between polyps and carcinomas since 
populations with a high incidence of colon polyps have an equally high incidence of CRCs. 
Furthermore, these studies also demonstrated similar prevalence rates between 
adenomas and CRCs regarding age, population and geographic areas, as well as similar 
risk factors. 
In most cases, the "adenoma-carcinoma" pathogenetic pathway initially involves the APC 
(Adenomatous Polyposis Coli) gene, a mutation of which is present in 80% of sporadic 
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cancers. Mutations of the APC gene cause a reduced degradation of beta-catenin leading 
to its subsequent nuclear accumulation, resulting in an alteration of intercellular contact 
and abnormal cell proliferation. This first mutation is followed in time by additional genetic 
alterations such as mutations of the KRAS gene, an oncogene involved in intracellular 
signalling that is mutated in about 50% of cancers of the colon, Loss of Heterozygosity 
(LOH) of chromosome 18q21, mutation of the PIK3CA, and deletion of the TP53 gene 
found in 70-80% of colonic malignancies. P53 plays the role of guardian of the genome, 
and its protein regulates basic cell processes, such as cell cycle and apoptosis. Although 
this sequence of events is observed in the majority of sporadic tumours, the accumulation 
of various mutations is more important than their specific order of occurrence [13]. 
Figure 1. Adenoma of the rectum with associated invasive carcinoma 
(kindly donated by Prof. Tibor Tot, University of Falun, Sweden) 
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Furthermore, it has been shown that the KRAS gene, when mutated, favours the 
uncontrolled replication of cancer cells, reducing the sensitivity to chemotherapy treatment, 
related therefore with a worse prognosis of the disease. In this perspective, the genetic 
test for KRAS mutations plays an important role in clinical practice, allowing to identify 
which patients would benefit from oncological treatment [14]. 
The evolutionary "adenoma-carcinoma" sequence can be found in most colorectal 
cancers, and this is particularly evident when the tumours develop from an existing 
epithelial polyp [12]. Most colon polyps are usually single or in some cases, several polyps 
can be found during the same examination. There are polyposis syndromes in which 
hundreds or even thousands of polyps develop in the colon and rectum, and often also in 
other sections of the gastrointestinal tract. The majority of the polyposis are rare hereditary 
syndromes with an increased risk of developing colorectal tumours. The diagnosis of these 
syndromes is based on the presence of numerous polyps in the GI tract, mainly in the 
colon, in more than one member of the same family, most members of which carry specific 
genetic alterations. 
 
1.2.1.1    Familial adenomatous polyposis syndrome  
 
Familial Adenomatous Polyposis (FAP) is a rare autosomal dominant syndrome with high 
penetrance. Patients with FAP develop CRC in 100% of cases (Figure 2), about 20 years 
earlier compared to sporadic CRC. FAP is characterized by the development of hundreds 
to thousands of adenomatous polyps, starting early in life, usually present before the age 
of 30. Polyps may also develop in other parts of the GI tract, such as glandular polyps of 
the stomach and adenomas of the duodenum. 
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Figure 2. Endoscopic appearance of Familial Adenomatous Polyposis 
 
An attenuated form of Familial Adenomatous Polyposis (AFAP) is characterized by the 
development of less than 100 polyps, mainly located in the left colon. In AFAP, the 
average age for the development of adenomas and CRCs is older compared to subjects 
with FAP. 
Rare variants of FAP are represented by Turcot and Gardner syndromes. The latter is 
characterized by the association of adenomatous polyps with fibromatosis, epidermal cysts 
and osteomas, mainly of the skull, the mandible and of the long bones. In the Turcot 
syndrome, colonic adenomas are associated with tumours of the central nervous system, 
in particular medulloblastomas. 
FAP is caused by a germline mutation of the Adenomatous Polyposis Coli gene, located 
on the chromosome 5q21, which can be identified by genetic testing. AFAP develops due 
to a mutation at the 5’ or 3’ extreme of the APC gene or in specific areas of exon 6 [15,16].  
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The MYH-associated polyposis (MAP), an autosomal recessive condition characterized by 
the presence of multiple adenomas and CRCs associated with biallelic inactivation of the 
MYH gene, shows similar clinical aspects to AFAP. Thus, MYH gene mutations should be 
investigated in all patients with clinical aspects of FAP or AFAP without a mutation in the 
APC gene. Diagnosis should be performed in early stages of life in order to start 
endoscopic screening by the age of 10-12 years. If the high number of polyps does not 
allow an appropriate endoscopic surveillance, prophylactic surgical colectomy is 
mandatory.  
 
1.2.2 II - The Microsatellite Instability (MSI) pathway  
 
The MSI pathway is involved in approximately in 10-15% of colorectal tumours [17,18]. 
The microsatellites are highly polymorphic DNA sequences formed by repetitions of single 
nucleotides (mononucleotides) or pairs of a subunit represented by di, tri, or 
tetranucleotide. Alterations of the length of these sequences, inside or nearby genes 
controlling cell proliferation, may modify qualitatively or quantitatively the product of these 
genes, thus playing a key role in tumorigenesis. The identification of colorectal carcinomas 
with high microsatellite instability (MSI-H) has also an important clinical significance, 
because these tumours have specific features such as being most frequently localized in 
the proximal colon, poor differentiation, mucinous or undifferentiated histology and intense 
intratumoural and peritumoural lymphocytic infiltrate [19]. Moreover, patients with MSI-H 
sporadic tumours have a better prognosis and an increased median survival regardless of 
the stage of the tumour, although these patients have an increased risk of developing 
metachronous cancer [20].  
Clinicopathological and molecular features 
of sporadic early onset colorectal cancer 
 
 
 
14 
 
 
 
The identification of colorectal carcinomas with MSI-H is clinically important since these 
tumours are characterized by more frequent location in the proximal colon, are more 
resistant to 5-FU chemotherapy but display more frequently a less aggressive behaviour.  
The microsatellite instability analysis is performed on a number of specific loci; in 
particular, the microsatellites panel recommended by the National Cancer Institute include 
loci BAT25, BAT26, D2S123, D17S250 D5S346e [21,22].  
The pathogenetic basis of the microsatellite pathway is due in most cases to a mutation of 
one of the genes (MLH1, MSH2, MSH6, PMS2 and Epcam) belonging to the group of the 
Mismatch Repair genes (MMR); these genes are involved in controlling and repairing 
errors of DNA replication. Their inactivation induces a state of “genomic instability” 
particularly affecting the microsatellite regions.   
In most cases, the tumours with MMR deficiency are predominantly sporadic, caused by 
epigenetic inactivation of MLH1 by promoter hypermethylation. However, in approximately 
20-25% of tumours with microsatellite instability, an inherited mutation (germline mutation) 
of one of the MMR genes can be found; such genetic alteration is responsible for the 
development of the Lynch syndrome (or HNPCC: Hereditary Non Polyposis Colorectal 
Cancer). In addition to the analysis of microsatellite sequences, the use of 
immunohistochemistry (IHC) with monoclonal antibodies anti-protein MLH1, MSH2, MSH6 
and PMS2 has been developed in recent years as a valuable diagnostic test to detect 
defective expression of MMR genes as genetic mutations for Lynch syndrome [23]. 
In addition, to distinguish sporadic colorectal tumours with high microsatellite instability, 
due to methylation of MLH1, from those associated with Lynch syndrome that have a 
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hereditary mutation in one of the MMR genes, it has been proposed to evaluate the 
presence of mutations in the BRAF gene. This gene appears in fact mutated in 
approximately 80-85% of the tumours with MSI and MLH1 methylation, while in cases of 
HNPCC no mutation occurs, thus, making the analysis of BRAF useful and reliable to 
identify families with Lynch syndrome [24].  
A distinction must be made for those families who meet the clinical criteria for the 
diagnosis of HNPCC (Amsterdam criteria [25,26]) but which have microsatellite stability 
and in which no mutation of the MMR genes is found. Various names have been proposed 
for this variant, such as "Clinical HNPCC" or "Familial Syndrome X". This distinction 
becomes particularly important as this syndrome shows different clinical characteristics 
from HNPCC, such as an later onset age and a more frequent localization of the lesions in 
the distal colon [27,28]. 
 
1.2.2.1   Hereditary Non Polyposis Colorectal Cancer (Lynch syndrome) 
 
This syndrome is a clinical condition characterized by the onset of colorectal cancer, 
endometrial cancer and other malignancies, whose development is transmitted in an 
autosomal dominant or recessive way with a penetrance that can reach 80-90%. This 
syndrome includes in up to 2-3% of all cancers of the colon which have in most cases an 
early onset (often to below 45-50 years of age), a localization of the tumour in proximal 
colon, and a greater risk of developing multiple cancers in the same patient [29]. 
The "Amsterdam criteria" were developed by the International Collaborative Group on 
HNPCC to clinically identify cases of Lynch syndrome. To do so, these international 
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guidelines used several parameters such the young age of cancer onset, the number of 
colon cancers among members of the same family, the exclusion of FAP and the 
histopathological confirmation of each tumour. However, once it was discovered that 
germline mutations of MMR genes and the microsatellite instability were the bases for the 
development of CRCs, the Bethesda guidelines were developed, providing physicians 
specific clinical criteria (Table 2) to identify families or patients with Lynch syndrome in 
whom perform MSI analysis. 
 
Table 2. The Revised Bethesda Guidelines for testing colorectal tumours for microsatellite 
instability 
Tumours from individuals should be tested for MSI in the following situations: 
Colorectal cancer diagnosed in a patient who is less than 50 years of age. 
Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumours,* 
regardless of age. 
Colorectal cancer with the MSI-H histology diagnosed in a patient who is less than 60 years 
of age. 
Colorectal cancer diagnosed in one or more first-degree relatives with an HNPCC-related 
tumour, with one of the cancers being diagnosed under age 50 years. 
Colorectal cancer diagnosed in two or more first- or second-degree relatives with HNPCC-
related tumours, regardless of age. 
*endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain tumours 
 
Nevertheless, despite meeting the Amsterdam criteria regarding the clinical diagnosis of 
HNPCC, in some cases families do not show MSI or mutation of the MMR genes. Various 
names have been proposed for this variant, such as "Clinical HNPCC" or "Familial 
Syndrome X". 
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Identifying families with Lynch syndrome allows to implement surveillance and early 
diagnosis. The "lifetime risk" of colorectal cancer in families with MMR mutation is 28-75% 
in men and 24-52% in women. In these cases, colonoscopy is recommended every 1 or 2 
years starting from 20-22 years of age, in order to reduce the risk of CRC by more than 
60% [23]. 
 
1.2.3 III – The CpG Islands methylator Phenotype pathway  
 
This pathway is related to the presence of hypermethylation of the promoter of several 
genes, in particular of tumour suppressors, leading to a consequent silencing of such 
genes. This pathway is most frequently associated with CRCs developing from serrated 
adenomas. The CIMP+ colorectal cancers frequently present a mutation of the BRAF 
gene, member of the RAF kinase family of growth-signal transduction protein kinases, 
whose deficiency reduces apoptosis. 
 
1.3 Clinical features of colorectal cancers 
 
 
1.3.1 Sporadic colorectal cancer 
 
The adenocarcinoma is most common type of CRC representing almost 95% of cases. 
The remaining 5% includes lymphomas, carcinoids and squamous cell carcinomas. In 
most case series, 55-65% of CRCs develop in the left colon and rectum, whereas multiple 
carcinomas are found from 3 to 6% of cases [30].  
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From a macroscopic point of view, right colon cancers tend to grow more frequently as 
exophytic masses, while tumours from the left colon show usually a depressed form or 
have an annular shape, affecting the entire circumference of the colon, causing stenosis 
and obstructive symptoms.  
Histological features of adenocarcinomas from the right and left colon are similar, although 
the mucoid forms are more frequent in the proximal colon. The histological pattern may 
range from well-formed glandular structures to poorly differentiated irregular masses. 
Extracellular mucin can be observed in tumour stroma in which the neoplastic cells appear 
to float; inflammatory or desmoplastic aspects may be particularly evident at the margins 
of the tumours. Necrosis is usually abundant and cellular mitosis, often abnormal, can be 
numerous. The neoplastic cells tend to infiltrate nerves, blood vessels and the intestinal 
wall as far as the serosa. All these parameters are useful for determining the stage of the 
disease. 
CRC symptoms depend on the stage, size and location of the tumour. Indeed, cancers of 
the caecum and right colon, more frequently lead to microcytic anaemia from chronic blood 
loss, fatigue, weakness or unexplained weight loss. On the contrary, CRCs that are more 
distal may cause acute rectal bleeding, abdominal pain and discomfort, and changes in 
bowel habits. The presence of a palpable mass or of obstructive symptoms develop during 
the advanced stages of the disease due to the invasive tumour growth. Perforation is a 
late complication and when it occurs, it is often related with high mortality rates. Other 
symptoms can develop due to cancer invasion and compression of adjacent structures 
such as bladder, ureter, vagina, or to local and distant metastases, mainly lymph nodes 
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and liver. Nevertheless, usually the symptoms appear vague and nonspecific, often 
indicative of an advanced stage of the disease at the time of the diagnosis. 
In the presence of the previously mentioned symptoms, or in case of positive Faecal 
Occult Blood Test (FOBT), the diagnostic confirmation of the presence of a CRC is 
generally easily obtainable with a colonoscopy. 
The introduction of screening programs has significantly increased the detection of CRCs 
in early stages, before they develop symptoms, thus reducing both morbidity and mortality. 
Indeed, the stage of the cancer is most important factor that affect the prognosis. For 
instance, when the tumour is considered operable, surgery can be curative with a 5-year-
overall survival ranging between 55 and 75% [31]. Moreover, for stage I lesions, that are 
confined to the submucosa and muscularis mucosa, the 5-year survival is greater than 
90%, whereas it declines to 70% when the tumour infiltrates beyond the muscularis (stage 
II). In the presence of lymph node metastases, the survival rate drops to 40-50%, while if 
lung or liver metastases are present, the 5-year survival is approximately 20% [31]. 
 
1.3.2 Early onset colorectal cancers 
 
Approximately, 15% of CRCs occur before the age of 50, mostly related with inflammatory 
bowel diseases (IBD), hereditary nonpolyposis colon cancer, and polyposis syndromes of 
the gastrointestinal tract. In this high-risk population, early endoscopic screening has 
shown to be effective in reducing mortality from colorectal cancer [32]. However, up to 5-
7% of colorectal cancers occur in patients with less than 50 years of age (Early Onset 
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Colorectal cancers - EOCRC) with no evidence of familial predisposition or belonging to 
hereditary syndromes [33].  
During recent decades, a significant rise in CRCs incidence and mortality has been 
reported in young adults under 50 years of age at diagnosis in many parts of the world 
[7,34-36], although the aetiology of this increase is currently unknown. Increasing 
incidence is mostly driven by rising rates of rectal cancer, as seen from 1992–2005 in the 
United states where young-onset rectal cancer has increased by 3.5% per year in men 
and 2.9% per year in women [4].  
These early-onset neoplasms are located most often at the level of the left colon and 
present a more aggressive clinical behaviour. Case series of early-onset colorectal 
neoplasms have been studied and analysed [33,37,38], however, little is known about why 
young adults without a predisposing genetic abnormality develop colorectal cancer and the 
pathogenetic pathway that leads to the early onset of these tumours has not yet been 
clarified. 
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2 OBJECTIVE AND AIMS OF THE STUDY 
 
 
The overall objective of the study is to improve diagnosis, treatment and prevention of 
early onset colorectal cancers, by studying a large population of patients younger than the 
age of 50, who present no predisposing genetic risk factors at the time of diagnosis.  
The specific aims include: 
  defining the clinicopathological features and the stage at presentation of sporadic 
early onset colorectal cancers  
 
 understanding whether the histological, immunohistochemical and molecular analyses 
associate with particular clinicopathological and oncologic follow-up parameters of 
sporadic EOCRCs. 
 
 understanding whether the early onset colorectal cancers may be defined as a distinct 
entity when compared to a consecutive series of sporadic CRCs that underwent 
surgery, with respect to their clinicopathological, histological and/or molecular features. 
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3 METHODS 
 
 
3.1 Patient selection 
 
To identify the cases of early onset colorectal cancer reported between 2006 and 2014, 
the prospectively maintained databases of the two oncological surgeries were reviewed 
together with the registries of the pathology department of the Sant’Orsola-Malpighi 
University Hospital. Only patients younger than the age of 50 were included in the study. 
Inclusion criteria were as follows: the diagnosis of colorectal adenocarcinoma confirmed 
on pathology; no presence of other types of colon cancer such as squamous cell 
carcinomas, carcinoids or lymphomas; no patients that had hereditary nonpolyposis colon 
cancer, inflammatory bowel disease, polyposis syndrome, or had a known family history 
for these conditions. 
Patients with a positive family history for sporadic colorectal cancer or cancers at sites 
other than the gastroenterological tract were not excluded from analysis. Altogether, 94 
EOCRCs and were found and included in the study. 
Moreover, to compare the data of EOCRCs, a consecutive series of 192 sporadic CRCs 
that underwent surgery in the same Hospital and that had been analysed as reported in a 
previous study by our research group was reviewed and used as a control group [39]. 
The medical records from all EOCRC patients were reviewed and the following data was 
extracted: patient demographics; comorbidities; family history for colorectal or other 
cancers; alcohol use; smoking; presenting symptoms for the EOCRC group; date of 
surgery; Tumour-Node-Metastasis (TNM) staging (Table 4); pathologic staging (Table 3); 
pattern of growth; tumour grade of differentiation: well, moderate, or poor; mucinous 
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adenocarcinoma: mucinous differentiation of more than 50% of the tumour; location of the 
tumour defined as right sided (cecum, ascending colon, hepatic flexure, transverse colon) 
or left sided (splenic flexure, descending colon, sigmoid colon) or rectum. Moreover, the 
presence of synchronous cancers was taken into consideration when a secondary lesion 
was found away from the primary tumour at the time of diagnosis. 
 
Table 3. Colorectal cancer staging systems 
Stage T N M Dukes 
0 Tis N0 M0 -- 
I T1 N0 M0 A 
 T2 N0 M0 A 
IIA T3 N0 M0 B 
IIB T4a N0 M0 B 
IIC T4b N0 M0 B 
IIIA T1-T2 N1/N1c M0 C 
 T1 N2a M0 C 
IIIB T3-T4a N1/N1c M0 C 
 T2-T3 N2a M0 C 
 T1-T2 N2b M0 C 
IIIC T4a N2a M0 C 
 T3-T4a N2b M0 C 
 T4b N1-N2 M0 C 
IVA Any T Any N M1a D 
IVB Any T Any N M1b D 
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Table 4. TNM classification for colorectal cancer 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumour deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal 
tissues without regional nodal metastasis 
N2 Metastasis in 4 or more lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site (liver, lung, ovary, nonregional node) 
M1b Metastases in more than 1 organ/site or the peritoneum 
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Regarding the control group, the following data were available: patient demographics; 
Tumour-Node-Metastasis (TNM) staging; pathologic staging; pattern of growth; tumour 
grade of differentiation: well, moderate, or poor; mucinous adenocarcinoma: mucinous 
differentiation of more than 50% of the tumour; location of the tumour defined as right 
sided (cecum, ascending colon, hepatic flexure, transverse colon and splenic flexure) or 
left sided (descending colon, sigmoid colon and rectum). 
 
 
3.2 Molecular analyses 
 
Records from the pathology department were reviewed searching for available molecular 
data for each included case of EOCRC. In particular, the data on routinely performed 
analyses was collected, including KRAS and BRAF genotype, MLH1 and MSH2 protein 
levels, as well as Ki-67, p53 and TS protein levels. 
In case of lacking data, if material was available, analysis were completed for the 
remaining cases, in particular regarding KRAS (codons 12 and 13) and BRAF codon 15 
(V600E) mutational analysis, performed using direct sequencing of polymerase chain 
reaction (PCR)–amplified products [40], and the MMR proteins immunohistochemistry 
staining (Figure 3). For the latter, the sections containing neoplastic tissue fixed in formalin 
and embedded in paraffin were immunostained by using the automatic processing 
immunostainer Benchmark Ultra Company Ventana (Ventana Medical Systems, USA). 
The processing protocols were as follows: anti-MLH1 clone M1 pre-diluted, Antigen 
Retrieval (AR) with Ultra CC1 for 32 Min. At 95 ° C, incubation for 16 Min. At 37 ° C, with 
detection system OptiView DAB + amplification detection kit; Antibody anti-MSH2 clone 
Clinicopathological and molecular features 
of sporadic early onset colorectal cancer 
 
 
 
26 
 
 
 
G219-1129 pre-diluted, AR with UltraCC1 for 52 min at 95 ° C, incubation for 32 min at 
36°C, with detection system UltraView DAB detection kit + Amplification. The whole 
neoplastic population was evaluated by selecting randomly at least 30 fields at 200x for a 
minimum number of 5,000 cells. The evaluation was performed by IMAGE-Pro Plus v.5.0.1 
software (Media Cybernetics Inc., USA). The final value was expressed as a percentage of 
the positive neoplastic population. The cut-off used to identify cases with significant loss of 
expression of MLH1 or MSH2 (High instability) was <= 1%.  
 
Figure 3. MSH2 immunohistochemical staining 
  
 
For the IHC analysis of p53 and TS, sections were stained using monoclonal anti-p53 
(clone BP53.12, Novocastra Laboratories, Newcastle-upon-Tyne, England) and anti-TS 
(clone TS106, Zymed Laboratories) antibodies and following previously described 
protocols [39]. Cytoplasmic TS immunoreactive population was evaluated according to 
positive tumour cell percentage and staining intensity as follows: score 0 if <1%, score 1 if 
>1% <20%, score 2 if >20% <50%, score 3 if >50% <80%, score 4 if >80%; intensity: 
score 1 (weak), score 2 (moderate), and score 3 (strong). A final score was considered by 
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adding the two score values as follows: negative (range 0-2), low (3-5), and high (6-7) 
expression. Nuclear immunostaining of p53 was classified as negative for cut-off values 
<10% [39]. 
 
3.3 Oncological follow-up and outcome 
 
 
The records of the two Oncology Departments of the University Hospital were queried to 
extract data regarding oncological treatment and postoperative follow-up of EOCRCs.  
In particular, the following data were extracted: use of neoadjuvant therapy, use of 
adjuvant treatments, treatment duration (number of cycles), treatment side effects, 
surveillance regimens, development of local and distant recurrence, need for further 
treatment (oncological or surgical) and tumour-related death. In particular, the date and 
site of the first tumour recurrence was extracted, and recurrences were categorized as 
local if they were perianastomotic and as distant if they involved lymph nodes, liver, lung, 
or other distant organs. 
Patients were followed to their date of death or their last contact with the medical centre. 
 
 
3.4 Statistical analyses 
 
Data were summarized using frequencies and percentages for all categorical variables, 
and all continuous variables were described as means with standard deviations. 
Categorical variables were compared using the chi-square test or Fisher’s exact test as 
appropriate, whereas the continuous variables were analysed using two-tailed unpaired t 
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test, with considering significant the differences for which p<0.05. Cancer survival rates 
were calculated from the date of diagnosis using the Kaplan–Meier method. 
Data were entered into Microsoft excel spreadsheet and subsequently imported into 
Medcalc software for windows, version 16.1, for statistical calculations. 
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4 RESULTS AND DISCUSSION 
 
4.1 Clinicopathological features of early onset colorectal cancers 
Over a 10-year period, between 2005 and 2014, 94 patients with adenocarcinoma of the 
colon-rectum diagnosed before the age of 50 years and operated at the University hospital 
Sant’Orsola-Malpighi were included in the study. The distribution according to gender was 
similar, with males and females representing 54% and 46% of cases, respectively. 
The mean age at surgery was 43.2 ± 3.9 years, distributed as follows: 48 were 45-49 
years old, 28 were 40-44 years old, 13 were 35-39 years old, 4 were 30-34 years old and 1 
was under 30 years of age. Such a distribution in age of EOCRC is in line with data 
published in previous studies [8]. 
Demographic and clinical features of all included cases are listed in table 5. 
The most common site of primary tumour was the rectum (40%), followed by left colon 
(32%) and right colon (27%). Figure 4 shows the specific location of EOCRCs in the 
colorectum. Synchronous malignant lesions were noted in four patients (4.3%). 
Seventy-eight (83%) patients were symptomatic at the time of diagnosis. The most 
common presenting symptoms were abdominal pain (34%), haematochezia (22%), rectal 
bleeding (21%) (Table 6). Of the 16 asymptomatic patients, evaluations were pursued 
mainly due to finding of anaemia, positive faecal occult blood test abdominal or presence 
of a mass. Patients with rectal cancer were more likely to present with the symptoms 
compared to colon cancer, although this tendency was not statistically significant (92% vs. 
77%, p = 0.07). 
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Table 5. Demographic and clinical features of the cohorts 
  
EOCRCs 
 (n=94) 
CRC Controls CRCs 
(n=192)  
Age, years (Average ± SD) 43.2 ± 3.9 67.3 ± 12.1 
Sex                                                                                                                   
  Male 51 (54%) 107 (56%)    
  Female 43 (46%)  85 (44%) 
BMI (Average ± SD) 23.7 ± 3.5 N/A 
Alcohol (>35 gr/die ) 20 (21.3%) N/A 
Smoking 35 (37.2%) N/A 
Dyslipidaemia 10 (10.5%) N/A 
Location   
   RIGHT COLON 30 (32%) 83 (43%) 
   LEFT COLON 64 (68%) 109 (57%) 
 
 
Clinical features at presentation in this cohort are similar to those found in other published 
series on young onset CRC. Indeed, the two most common symptoms at presentation, 
reported both in systematic reviews and in large cohort studies, are rectal bleeding and 
abdominal pain, since most studies include haematochezia among the rectal bleeding 
cases [41,42].  
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Figure 4. Specific location of EOCRCs in the colorectum 
 
 
Regarding tumour staging, half of EOCRCs showed an advanced stage with either stage 
III (34%) or stage IV (16%) upon presentation. Moreover, 44% of patients had lymph node 
localization (N1 or N2) and 12% had already distant metastasis (M1) at presentation 
considering the TNM staging. The issue of a late diagnosis of EOCRC is well known and is 
related to the fact that almost all cases are diagnosed due to the presence of symptoms 
developed during more advanced stages of the disease. Moreover, late diagnosis may 
also result from the clinician’s failure to consider the possibility of malignant disease in the 
differential diagnosis due to the young age [41]. 
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Table 6. EOCRCs presenting symptoms at first diagnosis* 
Symptoms N. of cases 
Abdominal pain  32 (34%) 
Haematochezia 21 (22.3%) 
Rectal bleeding 20 (21.3%) 
Change in bowel habits 16 (17.1%) 
Other 12 (12.8%) 
Anaemia  10 (10.6%) 
Weight loss  5 (5.3%) 
Weakness 4 (4.3%) 
FOBT positive 4 (4.3%) 
* Numbers total more than 100% because subjects were allowed to have multiple presenting symptoms 
 
Histologically, 10% of the cancers were well differentiated, 70% were moderately 
differentiated, and 20% were poorly differentiated. Mucinous and singlet cell histology was 
seen in 20 (21%) and 2 (2%) cases, respectively. Finally, the majority of EOCRCs showed 
an infiltrating tumour growth. 
These finding are in accordance with the histological features reported in previous case 
series of EOCRCs [41]. 
 
4.2 Comparison between EOCRCs and CRC control group  
 
The control group was composed by 192 consecutive patients surgically resected for 
sporadic colorectal cancer (thus, not belonging to known HNPCC or FAP families), and 
collected during the year 2001 at the Policlinico S.Orsola. 
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Demographic and clinical characteristics of all CRCs are reported in table 5. 
The mean age of this group was 67.3 ± 12.1 (Figure 5B). Male gender represented 56% of 
cases, similar to the EOCRCs group, indicating that there is no gender bias for 
development of EOCRC (Figure 5A). 
 
Figure 5. Gender (B) and age (B) distribution in the two cohorts 
 
 
Regarding cancer location, 57% of the control CRCs were located in the left colon, 43% in 
the right colon and the rectum. The incidence of rectal cancer was not reported separately. 
When compared to the EOCRC group the difference regarding the tumour location was 
not significant (p=0.16) (Figure 6). This result is in line with the data currently available 
from the literature. Indeed, a higher incidence of left colon cancers is present if the cancers 
related to hereditary syndromes are excluded. In particular, a higher incidence of rectal 
cancers among individuals under 50 years of age has been reported in several recent 
studies, reporting also an increase of the incidence in the last decades [41,43,44]. 
Moreover, higher rates of the right sided CRCs in patients less than 50 years of age are 
reported in studies that do not exclude tumours associated with Lynch syndrome. In fact, 
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this syndrome is well known to be associated with a higher incidence of cancers in the 
right colon in subjects younger than the age of 50, thus, endoscopic screening programs 
are started at an earlier age. In this study, having excluded cases of CRC-related 
syndromes, the prevalence of right colon location was not significantly associated with any 
of the two cohorts. 
 
Figure 6. CRC location in the two cohorts 
 
 
As far as tumour stage is concerned, stage II lesions were the most frequent in the control 
CRC population, accounting for almost half (47%) of the cases, no stage 0 or stage I 
cancers were present, whereas the advanced stages III and IV were present in 40% and 
13% of the cases, respectively. Similarly, in the EOCRCs group stage III and IV lesions 
represented 50% of patients, although stage IV cancers seem to occur more often (16%) 
(Figure 7), but this correlation is not statistically significant when compared to the control 
group (Figure 8). This is in line with the data regarding tumour differentiation, since 
EOCRCs showed a tendency of higher incidence of poorly differentiated tumours 
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compared to control CRCs (20% vs. 15%). Nevertheless, this latter difference was not 
significant (p=0.29) (Figure 9). Finally, in the control group mucinous histology was present 
in 15% of cases, whereas no singlet cell tumour was found in this group, compared to 21% 
of mucinous cases and 2 singlet cell cases in the EOCRC cohort. 
 
Figure 7. Tumour stage in the EOCRC group  
 
 
This analysis proves that no significant difference occurred between the two groups, 
although a tendency towards patients with EOCRC presenting with more locally advanced 
(more  stage IV and poorly differentiated tumours) and left sided cancers at the time of 
diagnosis is detected. More aggressive EOCRC features are found in most population-
based studies from Europe, Oceania, Asia, and the United States [41,45-47]. None of the 
cases in the two groups was diagnosed within a screening program, but only after 
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symptoms had developed, which explains the low percentage of cancers at an earlier 
stage.  
 
Figure 8. TNM staging in the two cohorts 
 
 
It is important to note that nowadays, with the implementation of screening programs, the 
early CRC detection in the adult population over 50 years of age is rising, whereas the 
diagnosis of EOCRC cannot be achieved during earlier stages since the screening 
programs do not include people under 50 unless they have high risk factors such as IBD or 
strong family history of CRCs. Moreover, the diagnosis of EOCRCs is also delayed due to 
patient-related factors, such as lack of access to medical check-ups, ignoring symptoms 
and patient denial, as well as to physician-related factors such as misdiagnosis, that taken 
together can account for at least 50% of delay in diagnosis [32,41]. 
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Figure 9. CRC grading in the two cohorts 
 
 
 
 
4.3 Evaluation of risk factors contributing to EOCRC development 
 
4.3.1 Family history for cancer 
 
 
A familial history for cancer overall and more specifically for CRC was detected in sporadic 
EOCRC patients after the careful evaluation performed in this study, despite a lack of 
reported hereditary conditions at the time of diagnosis. In particular, the EOCRC cohort 
comprised 17 patients (22%) with a first- or second-degree relative with colorectal cancer 
outside of a defined syndrome, such as FAP or HNPCC, and 43% with any type of cancer, 
regardless of location.  
Since the data on familiarity was not available for the CRC control group, the comparison 
was made with data form the regional tumour registry [48], which reports an overall 10% to 
15% of familiarity for CRC cases. On the other hand, the data from the literature report that 
a familial base is present in up to 25% of overall CRC cases [49]. In comparison, the 
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present EOCRC data lies in between the two values, which still confirms that more 
attention should be made at the time of diagnosis to the presence of a familial risk, also in 
terms of the genetic counselling of the proband.  
 
 
4.3.2 Smoking and Alcohol 
 
Smoking rate in the EOCRC group was 36%, while no data were available for the control 
group. Smoking is a known risk factor for CRC. The incidence of CRC is significantly 
higher in current as well as former smokers compared with lifelong non-smokers [50]. The 
prevalence of smokers in the EOCRC group showed to be higher than the overall 
prevalence of smokers in Italy (20.8%) as reported by the latest data from 2012 of the 
Ministry of Health [51], and in particular, it was higher for the group of 25-44 years of age 
that showed 33.7% in males and 24.1% female. Thus, it could be speculated that 
compared to the average of the national population, patients with EOCRCs are more often 
smokers and this could be a risk factor that could be worth to further investigate. 
 
Regarding alcohol consumption, in the EOCRC group 21% of patients consumed a 
minimum of 35 gr of alcohol daily. No data about alcohol consumption was available for 
the control group. 
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Figure 10. Alcohol consumption in the general population [53] and in EOCRCs 
 
 
There is a strong scientific consensus acknowledging the association 
between alcohol drinking and several types of cancer. Similarly, alcohol consumption is 
associated with a modestly increased risk for development of cancers of the 
colon and rectum. Regular drinking increases the risk of developing colorectal cancer for 
1.5 times as compared to non-drinkers or occasional drinkers [52]. 
Nevertheless, in this study, alcohol drinking in the EOCRC group appears to be similar to 
the prevalence in the general population. In particular, daily alcohol consumption increases 
in the community from 9.2% in the 20-24 years of age group to 23.9% in the 45-54 years 
of age group, whereas the overall prevalence is 22.1% (Figure 10) [53]. Thus, alcohol 
consumption does not seem to be a risk factor for development of EOCRC, when 
compared to healthy population. 
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4.3.3 Obesity and dyslipidaemias 
Epidemiological studies clearly indicate a correlation between obesity and colorectal 
cancer, and several mechanisms have been proposed and investigated that are linked 
with obesity-associated insulin resistance and chronic inflammation [10]. 
In the EOCRC group described in this study, the majority of patients showed a normal 
weight, with a mean BMI value of 23.4. On the other hand, in the general Italian population 
the rate of obese and overweight subject is higher among the 35-49 year olds, 9.5% and 
31.7%, respectively, as reported by the latest data from the Ministry of Health [54]. Thus, 
in this study, obesity seems not to be associated with the development of CRC in younger 
patients. 
This result further confirms that the mechanism involved in the association between 
obesity and colorectal cancers have probably a later effect in life, affecting mainly people 
over 50 years of age. Nevertheless, it should be noted that this association may be due to 
different life-styles of younger and older population, and thus may have no direct 
connection to CRC development. Moreover, the lower weight of subjects with EOCRCs 
may be due to the neoplastic-related loss of weight and cachexia, due to the later stages 
of the disease.  
 
 
4.4 Molecular features 
 
Colorectal cancer related to microsatellite instability is due either to a germline mismatch 
repair gene mutations, or to 'sporadic' somatic tumour MLH1 promoter methylation. Thus, 
IHC analysis of the MMR genes is used to detect cancers with MSI. In the two cohorts, 
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7.2% of cases with lack of MLH1 expression were found in the EOCRC group and 9.9% in 
the control CRC group. It is interesting to note that all cases of MLH1 deficiency also 
showed BRAF V600E mutation, thus correlating it to MLH1 promoter methylation [55]. No 
cases showing lack of expression of MSH2 protein were found in the EOCRC cohort, while 
4.7% were present in the control. 
The low number of cases showing lack of MMR proteins reported in this study compared 
to cohorts described in literature in patients younger than 50 year of age is mainly due to 
the selection criteria. Indeed, patients known to be part of families with Lynch syndrome 
were excluded from the analyses since the aim of the project was to characterize 
specifically the sporadic EOCRCs. Surprisingly, in the control group the number of cases 
was superior, although overall not significantly different when compared to the EOCRCs 
(p=0.22). An explanation could be that since familial predisposition and the presence of 
hereditary syndromes is more often investigated for CRCs developing in younger subjects 
than in patients older than 50 years, thus the control group probably comprised a few 
unknown hereditary tumours.  
KRAS mutation is an early event in the development of colorectal cancer and literature 
reports 30% to 40% of positive CRC cases. However, the prognostic role for KRAS in CRC 
remains controversial. On one hand, mutations in KRAS have been associated with a 
more advanced disease and a worst outcome. On the contrary recent studies showed that 
KRAS mutation was not a prognostic factor for therapy outcome [43,56,57]. 
The data on KRAS analyses were available for 48 cases of the EOCRC and showed 
KRAS mutation in 18 cases (37%). This result is in line with the literature reporting 
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association of KRAS with more aggressive cancers, since EOCRC cohort showed a 
tendency of a high incidence of advanced disease. 
 
Figure 12. p53 protein levels in the two cohorts 
 
No substantial differences were found between EOCRC and control CRC groups 
regarding the IHC levels of the proteins routinely requested by the oncologist to guide 
treatment, namely p53 and TS. Literature reports alterations of p53 protein levels to be 
associated with worse survival for CRC patients treated with chemotherapy [58]. In both 
groups analysed in this study, IHC analysis showed low p53 levels in 36% of cases (Figure 
12). This indicates that the loss of p53 is not correlated to the age of onset of CRC. 
Thymidylate synthase (TS) is the target of the active metabolite of 5-fluorouracil, and its 
level of expression is the most important determinant of clinical efficacy of this drug. Low 
levels of TS in the tumour of patients with CRC is a predictor of response to treatment with 
5-FU, while high levels of TS in tumour correlate with a poor response to treatment [39]. 
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Figure 13. Thymidylate synthase (TS) protein levels in the two cohorts 
 
 
In this study population, the TS levels were similar between the two groups (Figure 13); 
therefore, it is unlikely that this marker could affect the response to treatment in the two 
groups. However, the role and the effect of these markers among the two groups needs 
still to be clarified. 
 
 
4.5 Follow-up and oncologic outcome 
 
After surgical intervention, EOCRC patients were transferred to the Oncological 
department either to undergo chemotherapy or simply to continue follow-up. Patients were 
followed to their date of death or their last contact with the medical centre. The median 
follow-up was 35 months (range 4 to 110). The relatively short follow-up of EOCRC 
patients could be due to the presence of a more advanced disease and thus the survival is 
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expected to be shorter. Secondly, younger patients who feel well after surgery are usually 
less compliant to completing the therapy due to side effects. 
 
Figure 14. Overall survival of EOCRCs 
 
 
Adjuvant chemotherapy was undertaken by 49% of patients in the EOCRC groups. 
The overall the 1-year survival was 91%, while at 5 years it dropped to 57% (Figure 14). 
The survival rate divided by tumour stage showed a survival rate of 100%, 79%, 54% and 
19% for stages I, II, III and IV, respectively (Figure 15).  
No significant survival rate differences were observed when comparing p53 levels, TS 
levels, MMR expression or cancer location. 
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Figure 15. Stage survival of EOCRCs 
 
 
The overall survival of the EOCRCs appears to be lower when compared to the overall 
survival reported for colorectal cancer in Italy, where the 5-year survival is 64% in men and 
63% in women according to the latest data [59]. These latter data include also cases 
diagnosed within the screening program, therefore diagnosed at earlier stage which is one 
parameter explaining the better survival. In fact, the overall survival before the introduction 
of the screening programs was around 58%, closer to the EOCRC rate reported in this 
study.  
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5 Concluding remarks 
 
 
The increasing occurrence of CRC developing in young patients with no identified genetic 
predisposition demands maintaining a high index of suspicion when people below 50 years 
of age present with symptoms. Indeed, EOCRCs appear frequently as an aggressive 
disease located in the sigmoid colon and rectum, and most patients are symptomatic at 
the time of presentation, mainly presenting with rectal bleeding, haematochezia or 
abdominal pain.  
The genetic basis in the majority of early onset colorectal carcinomas remains unknown, 
however, most EOCRCs, not related hereditary syndromes, appear to arise through the 
same pathways as sporadic CRCs, such as the classical adenoma-carcinoma sequence, 
but with only rare involvement of the methylator pathway. 
Taken together, the analyses described in this study suggest that, in the absence of 
screening programs for patients under 50 years of age, the risk factor of a family history 
and the presence of symptoms may be considered as an indication for prompt endoscopic 
investigation in these patients, since this may reduce the stage of disease at diagnosis and 
likely have an impact on improving survival. 
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